Neurokinin receptors

Image

The Journal of Dual Diagnosis: Open Access (ISSN:2472-5048) is going to Celebrate Four years of anniversary in the year 2020, It aims to disseminate knowledge and promote discussion through the publication of peer-reviewed, high quality research papers on all topics related to Dual diagnosis.

The neurokinins are a class of peptide signaling molecules that mediate a range of central and peripheral functions including pain processing, gastrointestinal function, stress responses, and anxiety. Recent data have linked these neuropeptides with drug-related behaviors. Specifically, substance P (SP) and neurokinin B (NKB), have been shown to influence responses to alcohol, cocaine, and/or opiate drugs. SP and NKB preferentially bind to the neurokinin-1 receptor (NK1R) and neurokinin-3 receptor (NK3R), respectively, but do have some affinity for all classes of neurokinin receptor at high concentrations. 

Neurokinins are stress-related neuropeptides that mediate drug-related behaviors. NK1 receptors are primarily involved in opiate reward and stress-induced relapse for most drugs. NK3 receptors mediate cocaine-induced behaviors and alcohol consumption.  NK1R and NK3R are valuable targets in medication development for addiction.

The journal invites different types of articles including original research article, review articles, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication. A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be submitted through the Email given below.

You can Submit manuscript directly online https://www.imedpub.com/submissions/dual-diagnosis-open-access.html or as an attachment to this E-mail: dualdiagnosis@emedsci.com

Articles will be paid high attention during the Publication any immediate submission is highly appreciable.

Regards,
Nancy Ella
Dual Diagnosis: Open Access
Email: 
dualdiagnosis@emedsci.com
WhatsApp no: +1-947-333-4405